Helicobacter pylori evasion strategies of the host innate and adaptive immune responses to survive and develop gastrointestinal diseases by Karkhah, A et al.
See discussions, stats, and author profiles for this publication at: https://www.researchgate.net/publication/328121492
Helicobacter pylori evasion strategies of the host innate and adaptive immune
responses to survive and develop gastrointestinal disease
Article  in  Microbiological Research · October 2018
DOI: 10.1016/j.micres.2018.09.011
CITATIONS
3
READS
112
8 authors, including:
Some of the authors of this publication are also working on these related projects:
Cancer Therapeutics View project
Association of Helicobacter pylori infection with Toll-like receptor-4 Thr399Ile polymorphism increased the risk of peptic ulcer development in North of Iran View
project
Ahmad Karkhah
Babol University of Medical Sciences
35 PUBLICATIONS   66 CITATIONS   
SEE PROFILE
Soheil Ebrahimpour
Babol University of Medical Sciences
56 PUBLICATIONS   148 CITATIONS   
SEE PROFILE
Veerendra Koppolu
MedImmune, LLC
18 PUBLICATIONS   120 CITATIONS   
SEE PROFILE
Veneelakrishnarekha Vasigala
Rangaraya Medical College
9 PUBLICATIONS   28 CITATIONS   
SEE PROFILE
All content following this page was uploaded by Hamid Reza Nouri on 13 October 2018.
The user has requested enhancement of the downloaded file.
Accepted Manuscript
Title: Helicobacter pylori evasion stra<!–<query
id="Q1">Please check country name.</query>–>tegies of the
host innate and adaptive immune responses to survive and
develop gastrointestinal disease
Authors: Ahmad Karkhah, Soheil Ebrahimpour, Maryam
Rostamtabar, Veerendra Koppolu, Sorena Darvish, Veneela
Krishna Rekha Vasigala, Majid Validi, Hamid Reza Nouri
PII: S0944-5013(18)30835-8
DOI: https://doi.org/10.1016/j.micres.2018.09.011
Reference: MICRES 26223
To appear in:
Received date: 18-7-2018
Revised date: 9-9-2018
Accepted date: 28-9-2018
Please cite this article as: Karkhah A, Ebrahimpour S, Rostamtabar M, Koppolu
V, Darvish S, Krishna Rekha Vasigala V, Validi M, Nouri HR, Helicobacter
pylori evasion strategies of the host innate and adaptive immune responses to
survive and develop gastrointestinal disease, Microbiological Research (2018),
https://doi.org/10.1016/j.micres.2018.09.011
This is a PDF ﬁle of an unedited manuscript that has been accepted for publication.
As a service to our customers we are providing this early version of the manuscript.
The manuscript will undergo copyediting, typesetting, and review of the resulting proof
before it is published in its ﬁnal form. Please note that during the production process
errors may be discovered which could affect the content, and all legal disclaimers that
apply to the journal pertain.
 evasion strategies of the host innate and adaptive Helicobacter pylori 
immune responses to survive and develop gastrointestinal disease 
Ahmad Karkhah1,2, Soheil Ebrahimpour3, Maryam Rostamtabar1, Veerendra Koppolu4, 
Sorena Darvish1 , Veneela Krishna Rekha Vasigala5, Majid Validi6, and 
Hamid Reza Nouri2* 
 
1. Student Research Committee, Babol University of Medical Sciences, Babol, I.R. Iran. 
2. Cellular and Molecular Biology Research Center, Health Research Institute, Babol University of Medical 
Sciences, Babol, I.R. Iran 
3. Infectious Diseases and Tropical Medicine Research Center, Health Research Institute, Babol University 
of Medical Sciences, Babol, I.R. Iran. 
4. Scientist Biopharmaceutical Development Medimmune Gaithersburg, MD, USA 20878 – 
5. Rangaraya Medical College, NTR University of Health Sciences, Kakinada, India 
6. Clinical Biochemistry Research Center, Basic Health Sciences Institute, Shahrekord University of 
Medical Sciences, Shahrekord, I.R. Iran. 
 
 
Corresponding author: 
Dr. Hamid Reza Nouri, Cellular and Molecular Biology Research Center, Health Research 
Institute, Babol University of Medical Sciences, Babol, Iran 
Tel: +98 11 32222033, Fax: +98 11 32229936 
E-mail: nourihr851@gmail.com 
 
 
Running title: escape strategies Helicobacter pylori 
 
 
List of abbreviation: 
H. pylori: Helicobacter Pylori 
PAI: Pathogenic islands 
Cag A: Cytotoxin-associated gene A 
Vac A: Vacuolating cytotoxin gene A 
MALT : Mucosa-associated lymphoid tissue 
 
AC
CE
PT
ED
 M
AN
US
CR
IPT
Abstract 
Helicobacter pylori H. pylori( ) is a bacterial pathogen that resides in more than half of 
the human population and has co-evolved with humans for more than 58000 years. This 
bacterium is orally transmitted during childhood and is a key cause of chronic gastritis, peptic 
ulcers and two malignant cancers including MALT (mucosa-associated lymphoid tissue) 
lymphoma and adenocarcinoma. Despite the strong innate and adaptive immune responses, H. 
pylori has a long-term surviv in the gastric mucosa. In addition to the virulence factors, al 
survival of is strongly inﬂuenced by the ability of bacteria to escape, disrupt and H. pylori 
manipulate the host immune system. This bacterium can escape from recognition by innate 
immune receptors via altering its surface molecules. Moreover, subverts adaptive H. pylori 
immune response by modulation of eﬀector T cell. In this review, we discuss the immune-
pathogenicity of by focusing on its ability to manipulate the innate and acquired H. pylori 
immune responses to increase its survival in the gastric mucosa, leading up to gastrointestinal 
disorders. We also highlight the mechanisms that resulted to the persistence of in H. pylori 
gastric mucosa. 
Key words: Adaptive immunity, Evasion strategies, Innate immunity, H. pylori. 
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1. Introduction 
Helicobacter pylori (H. pylori) as Gram-negative bacteria is the ﬁrst formally a 
recognized bacterial carcinogen and is one of the most successful human pathogen, as it infects 
approximately 4.4 billion (~ 59%) of the world's population (Hooi et al., 2017). H. pylori 
infection is typically acquired in early childhood (Gold, 2001), although precise estimation of 
age of occurrence is diﬃcult to obtain in young children. Despite severe innate and adaptive 
immune responses of human this pathogen it can survive in the gastric mucosa for a long to , time 
(Abadi, 2017). infection is the main cause o chronic gastritis, which is an H. pylori f 
asymptomatic disorder in most infected people. This bacterium is also a major cause of gastric 
and duodenal ulcers known as peptic ulcer and two malignant cancers such as gastric 
adenocarcinoma and mucosa-associated lymphoid tissue (MALT) lymphoma (Kusters et al., 
2006). The potential of to survive and to cause chronic infection is more than other H. pylori 
Gram-negative bacterial pathogens in the stomach (Testerman and Morris, 2014). The presence 
of in the gastric tissue is often observed in gastric mucosa close to the underlying H. pylori 
epithelial cells (Ebrahimpour et al., 2017). The initial colonization of the bacterium in the gastric 
mucus depends on several factors including the expression of the bacterial urease enzyme (to 
overcome the acidic conditions of the gastric lumen), possession of polar ﬂagella (for motility), 
and the changes in the bacterial cell morphology to eﬀectively penetrate the gastric mucosal 
barrier and gain access to the underlying epithelial cells. A number of bacterial virulence factors 
such as cytotoxic-associated gene A (CagA) and vacuolating cytotoxin (VacA), environmental 
factors, and host factors (host gene polymorphism) at the epithelium would increase the H. pylori 
colonization and susceptibility to the associated diseases (Dunne et al., 2014). The survival of H. 
pylori is also strongly inﬂuenced by the ability of the bacteria to escape, disrupt and manipulatse e 
the host immune responses. This bacterium can escape from being recognized by innate immune 
receptors via altering its surface molecules (Peek et al., 2010). can also block other H. pylori 
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innate recognition receptors by inhibiting downstream signaling pathways. On the other hand, H. 
pylori is able to escap from the host adaptive immunity by modulating the function of the e T 
lymphocytes (Wen and Moss, 2009). In this review article, we mainly discuss the considerable ed 
ability of this bacterium to manipulate and escape the innate and adaptive immune responses. 
2. Data collection 
A systematic review of studies evaluating the immune escape mechanisms of H. 
pylori from 1999 to 2018 was carried out in multiple databases. It should be noted that the related 
keywords, including ,“H. pylori,” “intrinsic and specific immune responses ” “immune escape” 
and “virulence factors” were used to ﬁnd these articles. Of the extracted articles that were related 
to the subject, 105 articles were reviewed. According to results of the mentioned studies, H. 
pylori escapes innate immune responses through various mechanisms such as escape from 
recognition by Toll-like receptors (TLRs) and RIG-I-like receptors (RLRs) along with activation 
of inﬂammasome complex. Furthermore, modulated adaptive immune responses H. pylori 
through suppressing the development of Th1 and Th17. Therefore, each of these mechanisms is 
explained in more details. 
3. colonization in the gastric mucosa H. pylori 
3.1. Continuous colonization in the stomach mucosa and escape from the acidic lumen 
The stomach lumen with acidic pH is not appropriate environment for bacterial an 
colonization. Thus, the highest bacterial density is visible in the lower bowel with neutral or 
slightly alkaline pH. Production of gastric acid in the stomach resulting in the creation of pH 1-
2 limits bacterial colonization in this region. can persist for just a few minutes the H. pylori in 
lumen of the stomach and must quickly migrate to the epithelial cells crossing the mucosal barrier 
(Schreiber et al., 2005 Schreiber et al., 2006). The mucous membrane layer of the stomach acts ; 
as a physical barrier against bacterial inﬁltration and traps host antimicrobial compounds to 
prevent bacterial infection (Hansson, 2012). produces urease enzyme responsible for H. pylori 
AC
CE
PT
ED
 M
AN
US
CR
IPT
gastric acid- resistance of bacteria via generation of ammonium ions, and movement of bacteria 
and penetration into the gastric mucosa by altering the viscosity of gastric mucins content 
(Sidebotham et al., 2003). At low pH, mucins convert into a gel status that eﬀectively traps 
bacteria, but in the presence of urease activity, pH will increase and subsequently, viscosity of 
the mucins will decrease, leading to the bacteria being able to swim in mucous layer (Celli et al., 
2009). Another mechanism that inﬂuences colonization is chemotaxis. H.pylori H. pylori 
expresses several chemotactic receptors and mutation in these chemotactic factors reduce the can 
number of bacteria that are in close proximity to gastric epithelial cells (Williams et al., 2007). 
H. pylori deﬁcient in chemotactic factors are also associated with reduced inﬂammation and 
defective eﬀector T cell responses, possibly due to lack of intimate contact with gastric epithelial 
cells (Johnson and Ottemann, 2018). , keeping away from direct contact with gastric So H. pylori 
epithelium will decrease the infection risk, while increasing the inﬂammation related to the close 
contact with epithelium simultaneously. In fact, high inﬂammation is inversely correlated with 
the low density of bacteria (Ghasemi Basir et al., 2017). These conditions highlight the fact that 
H. pylori should eﬀectively manage its contact with gastric epithelium until it is able to prevent 
clearance by the host immune responses and survive in this position (Suarez et al., 2006). 
 Some strains constitutively express DNA repair proteins such as RecA H. pylori 
and thereby eliminates the need for classical SOS response to DNA damage. DNA damage in H. 
pylori likely increases bacterial genetic diversity, instead of natural sustainability resistance. 
Most of the DNA repair pathways have been identiﬁed in and are involved in the H. pylori 
eﬀective colonization of bacteria (Dorer et al., 2011). Furthermore, all strains express H. pylori 
catalase and superoxide dismutase proteins that are important for the detoxiﬁcation of reactive 
oxygen species (ROS) (Benoit and Maier, 2016). Along with these enzymes, arginase limits the 
production of nitric oxide (NO) from monocyte, neutrophil, and epithelial cells (Lewis et al., 
2010) and thus promoting bacterial survival. also subverts autophagy of infected cells H. pylori 
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through inhibition of lysosomal clearance of autophagosomes. Inhibition of lysosomal function 
can promote accumulation of autophagosomes in gastric epithelial cells leading to bacterial 
survival (Zhang et al., 2018). The mentioned strategies increase survival and colonization of  H. 
pylori in stomach. 
3.2. Major cytotoxin associated gene pathogenicity island (cagPAI) products 
The cytotoxin-associated gene A (CagA) and Vacuolating cytotoxin A (VacA) molecules as 
two major toxins, which are encoded by pathogenicity island (PAI) genetic locus, are required 
for bacterial persistence in the stomach. Both CagA and VacA are known to aﬀect multiple host 
cellular processes for the successful establishment of the pathogen (Nejati et al., 2018). In 
addition to CagA and VacA expression, PAI encodes several proteins that form the structural cag 
components of the bacterial type IV secretion system. In some strains of , the PAI H. Pylori cag 
is completely absent (Nilsson et al., 2003). The PAI-positive strains in comparison cag H. pylori 
to PAI-negative strains, stimulate epithelial cells to produce high levels of IL-8 (cag Guillemin 
et al., 2002). In addition, peptic ulcer and gastric cancer occur more frequently in individuals 
infected with PAI-positive strains than PAI-negative strains (Algood and Cover, 2006). cag cag 
CagA, is a highly immunogenic protein encoded by th PAI and is associated with cell e cag 
injury, duodenal ulcers, and gastric adenocarcinoma. CagA is transmitted to the host cell after 
attachment of bacteria to epithelial cell surface through the type IV secretion system (T4SS). 
CagA can act in both phosphorylated and unphosphorylated states. CagA when phophorylated, 
interacts with a tyrosine phosphatase, SHP-2, and modulates migration, spreading, and adhesion 
of bacteria to the epithelial cells (Yamazaki et al., 2003). In recent years have shown that CagA 
positive strains of bacteria increase the risk of cancer (Pormohammad et al., 2018). 
Consequently, CagA was introduced as a bacterial oncoprotein that critically involved in gastric 
carcinogenesis.(Hatakeyama, 2003). 
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Another product of PAI is CagL that is expressed on the pilus of the T4SS and is required for 
CagA translocation. The CagL interacts with α5β1 integrin through its arginine-glycine-aspartate 
(RGD) motif on epithelial cells that translocate bacterial CagA (Cherati et al., 2017). 
VacA is a secreted pore-forming toxin that enters the host epithelial cells by endocytosis and 
aﬀects a variety of biological processes. Many strains of carry the VacA gene which H. pylori 
show a considerable amount of diversity in DNA sequences among diﬀerent strains. As a 
consequence, diﬀerent isoforms are associated with diﬀerential cell toxicity and severity of 
gastrointestinal disease (Palframan et al., 2012). VacA through several mechanisms may 
contribute to persistence in the stomach. VacA showed direct cell-damaging eﬀects H. pylori 
including cytoskeletal changes and suppression of epithelial cell proliferation (Pai et al., 1999). 
VacA as a pore-forming toxin causes apoptosis of epithelial cells (Nejati et al., 2018). Besides 
these mechanisms that may provide persistence, VacA blocks phagosome maturation H. pylori 
in macrophage cells (Zheng and Jones, 2003). Furthermore, VacA inhibits antigen presentation 
process to T cells, blocks T cell proliferation, and downregulates Th1 functions via interacting 
with calcineurin signaling pathway (Gebert et al., 2003). 
4. as a new challenge for the immune system H. pylori 
 Besides multiple virulence factors of leading to its survival, bacterium H. pylori 
manipulates host immune responses as a successful strateg in the development of y 
gastrointestinal disorders. The main defensive barriers against are the mucus secretH. pylori ed 
by epithelial cells and the innate immune cells in the lamina propria (Chmiela et al., 2017; 
Mejias-Luque and Gerhard, 2017). The immune responses against are initiated by the H. pylori 
recognition of the highly conserved pathogen-associated molecular patterns (PAMPs) by pattern 
recognition receptors (PRRs) on epithelial and innate immune cells, followed by initiation of the 
adaptive immune responses. This bacterium applies many evasion pathways to escape the innate 
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and adaptive immunity for the surviv in the stomach to cause diﬀerent gastrointestinal disorders al 
(Mogensen, 2009). These mentioned mechanisms have been summarized in ﬁgure1. 
4.1. Innate immunity evasion strategies 
The innate immunity is evolutionarily conserved in higher eukaryotes and is known 
as the ﬁrst line of defense against infections. Toll like receptors (TLRs) are the main cluster of 
PPRs that recognized PAMPs. Bacterial lipopolysaccharides (LPS), peptidoglycan, lipoprotein, 
lipoteichoic acid and un-methylated CpG rich regions of DNA are the main targets of TLRs 
(Takeda and Akira, 2004). The TLRs signaling applies adaptor proteins and then activate nuclear 
factor (NF)-kB, interferon regulator factor (IRF) and activator protein-1 (AP-1). Activation of 
these transcription factors results in inﬂammatory cytokines and chemokines along with IFN-α 
and IFN- (Kawasaki and Kawai, 2014). On other hand, TLRs signaling in dendritic β production 
cells (DC) pave the way for adaptive immune responses against . escapes from H. pylori H. pylori 
detection by a large variety of PRRs that are essential for the recognition of other intestinal Gram-
negative pathogens (Peek et al., 2010). 
4.1.1. Evasion from recognition by TLRs 
Currently, 11 members of TLRs family have been identiﬁed in mammals. TLRs are 
expressed on the surface of the plasma membrane or endosomes and bind to the diﬀerent classes 
of PAMPs (Satoh and Akira, 2016). Among the diﬀerent TLRs, TLR2, TLR3, TLR4, TLR5, and 
TLR9 are characterized in the context of infection and are recognized by lipoteichoic H. pylori 
acid /or lipoprotein, double-stranded RNA (dsRNA), LPS, ﬂagellin, and un-methylated CpG 
motifs, respectively (Akira and Takeda, 2004). Studies showed that successfully escapes H. pylori 
from recognition by the TLRs. For example, the TLR4 escapes of LPS recognition is well 
described. LPS activity is 1000 times less than LPS of . This H. pylori Escherichia coli (E. coli)
less activity of LPS in is related to tetra acylated form in comparison to hexa acylated H. pylori 
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LPS of (Stead et al., 2008). In addition, removal of phosphate groups from the 1' and 4' E. coli 
positions of lipid A in LPS induce the low negative charge to this molecule and increase the 
chance of escaping TLRs recognition. The responsible phosphatase for changes in lipid A was 
identiﬁed via site directed mutagenesis in this gene, the colonization of remarkably as H. pylori 
failed in infected mice (Cullen et al., 2011). Recognition of the LPS by TLRs is a controversial 
issue. Although many studies suggested the TLR4 is the main TLR for LPS binding, but other 
studies suggested TLR2 as key TLR in LPS recognition. In recent years, both TLR4 and TLR2 a 
have been introduced for recognition of the remaining PAMPs other than LPS of (Rad H. pylori 
et al., 2009). The recognition of non-LPS ligands by TLR2 exploits of innate immune responses 
for induction of anti-inﬂammatory responses that are associated with IL-10 production (Peek et 
al., 2010). Flagellin, another famous PAMP, is recognized by TLR5. Flagellin can modify the N-
terminal recognition domain of TLR5 and, then escape from innate immune responses. 
Manipulation of amino acid 89 96 of the recognition domain of TLR5 results in low aﬃnity to –
ﬂagellin binding (Gewirtz et al., 2004). The experiments performed on DC cells showed that the 
innate immune system also recognizes the nucleic acid of (Rad et al., 2009). Intracellular H. pylori
released of into DCs activates the endosomal accumulation of TLR9 leading to DNA H. pylori 
anti-inﬂammatory responses. A recent mouse model also showed that TLR9 signaling has anti-
inﬂammatory eﬀects in the early stages of infection (Varga and Peek, 2017). H. pylori 
Additionally, an experimental study conﬁrmed that DNA of could even inhibit H. pylori 
inﬂammatory bowel disease (IBD) development in the mouse. Later, this unique sequence of H. 
pylori with immune-regulatory properties was introduced and had a short speciﬁc sequence 
(TTTAGGG) of genome (Hansen et al., 2011). H. pylori 
4.1.2. Evasion from RLR recognition 
 H. pylori The RNA of be recognized via endosomally localized TLR8 on DC can 
(Pachathundikandi et al., 2015). The study has suggested that Retinoic Acid Inducible Gene 1 
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Protein (RIG-1), a cytoplasmic nucleic acid sensor, is involved in sensing the RNA. The RIG-I 
like receptors (RLRs) as a subfamily of PRRs, have been studied in infection. RLRs act H. pylori 
as cytoplasmic sensors of PAMPs. The RLR family has three members: RIG-I, which is the best 
characteristic of this family, melanoma diﬀerentiation associated factor 5 (MDA5), and 
laboratory of genetics and physiology 2 (LGP2) (Matsumiya and Staﬀorini, 2010). It is well 
known that RLRs induce type I IFN in response to RNA viruses, but the role of RLRs in 
recognition of RNA from intracellular bacteria is unclear. Rad et al. showed that -H. pylori 5′
triphosphorylated RNA can be recognized by RIG- in DCs and can contribute to the type I IFN I 
response (Rad et al., 2009). Further, MDA-5 expression signiﬁcantly increased in the gastric 
antral mucosa of -infected individuals (Tatsuta et al., 2012). It is currently unknown H. pylori
whether the production of type I IFNs in response to via RIG-1 has pro-inﬂammatory H. pylori 
or anti-inﬂammatory eﬀects (Sayi et al., 2011). 
4.1.3. Evasion from CLR recognition 
 C-type lectin receptors (CLRs) as the third class of PRRs bind to glycans present on 
viruses, bacteria, and fungi to induce immune responses. The well characterized receptor in this 
class is -speciﬁc intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN) that DC
expressed on the surface DCs and macrophages (van Kooyk and Geijtenbeek, 2003). The 
fucosylated ligands of recognized by DC-SIGN strongly dissociate the signaling H. pylori 
complex downstream of DC-SIGN leading suppression of pro-inﬂammatory cytokine to 
production. In contrast, most pathogens comprised -SIGN mannosylated ligands causing DS
activation of the pro-inﬂammatory pathways. The diﬀerent biological eﬀects of mannosylated 
and fucosylated ligands of DS-SIGN are applied via acetylation of NF-kB (Wu et al., 2014). 
Acetylation of the P56 subunit of NF-kB has been shown to prolong and increase the transcription 
of the IL-10 to enhance anti-inﬂammatory responses (Takeshima et al., 2009). Moreover, anti-
DC-SIGN signiﬁcantly suppressed induced IL-10 production in monocyte-derived DCs H. pylori 
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before stimulation. In fact, these strategies will justify the persistence of the organism H. pylori 
(Chang et al., 2012). 
4.1.4. The challenge of new players of innate immunity with ; NLRs and H. pylori
inﬂammasome 
Nucleotide-binding and oligomerization domain (NOD) -like cytoplasmic 
receptors (NLRs) are the fourth and the last family of PRRs. The NLRs detect a wide range of 
damage-associated molecular patterns (DAMPs that are created after disturbing tissue ) 
homeostasis (Land, 2015). Generally, NLRs are divided into two groups including NOD1 and 
NOD2. The NOD1 recognizes peptidoglycan in the cytoplasm of epithelial cells and H. pylori 
activates -kB signaling and its translocation to the nucleus. The NOD1 signaling causes NF H. 
pylori killing in the -defencin 2 as an antimicrobial peptide. activated epithelial cell through β
Overall, was reported to be recognized via NOD1 in epithelial cells and via NOD2 H. pylori 
in bone marrow derived DCs. Recently, experiments have shown that blocking of NOD1 –
cannot inﬂuence the NF-kB translocation (Minaga et al., 2018). 
The second category in NLRs strengthens the formation of a complex containing 
several proteins called inﬂammasome, which activates the cysteine protease of caspase-1 that 
control the processing of pro- -IL 1β  and  IL-18 (Tourani et al., 2018). The inﬂammasome 
involves a cytoplasmic sensor protein (NLRP1 (NLR family, pyrin domain containing 1), –
NLRP3, or NLR family, CARD domain containing 4 (NLRC4) of the NLR family), the –
adaptor protein apoptosis-associated speck-like domain containing CARD (caspase 
recruitment domain) (ASC) and procaspase-1. Establishment of the inﬂammasome complex is 
induced by a signal with speciﬁc aspects for the diﬀerent types of inﬂammasome (Guo et al., 
2015 Schroder and Tschopp, 2010). The inﬂammasome ligands and NLRs involved in ; H. 
pylori recognition are unknown. However, and studies indicated that caspase-in vivo in vitro 1 
is activated after co-culture with in DCs and IL-H. pylori 1β and IL-18 processed and released 
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into the gastric mucosa (Hitzler et al., 2012b). Recently following infection has shown H. pylori 
that potassium eﬄux, reactive oxygen species (ROS) and lysosomal destabilization are the key 
cellular targets responsible for activation of NOD and NLRP3 inﬂammasome. In addition, 
VacA and CagPAI were introduced as the bacterial virulence factors that are involved in 
inﬂammasome complex. Moreover, experiments indicated key role of the in vivo a 
inﬂammasome in the beginning and establishment of the inﬂammatory response to H. 
pylori infection (Semper et al., 2014). 
 There is no evidence indicating that escape of the inﬂammasome or H. pylori 
caspase-1. A study showed that caspase-1 deﬁcient mice could clear the experimental H. pylori 
infection more eﬀectively than the wild-type mice, and have more pathogen-speciﬁc T cell 
responses with more damages (Hitzler et al., 2012b). This unexpected observation was 
explained by -18 or IL-18R deﬁcient mice that indicated the critical role of IL-18 in CD4+ IL
CD25+ Foxp3+ Regulatory T Cells induction in response to Accompanied by the H. pylori. 
presence of Treg cells, the activity of eﬀector T cells will be limited and result in the persistence 
of the infection (Oertli et al., 2012). In contrast, - deﬁcient mice were unable to develop IL 1β 
the speciﬁc Th1 and Th17 that lead to expansion of experimental infections and mice H. pylori
were only protect against mildest forms of infection associated with immunopathology ed 
(Hitzler et al., 2012b). -IL 1β and IL-18 are important in the context of infection. Both H. pylori 
cytokines have been extensively linked to gastric carcinogenesis. Polymorphisms in the -IL
1β and IL-18 genes result in elevated levels of these cytokines that increase the risk of gastric 
cancer (Ramis et al., 2017). A study showed that speciﬁc expression of IL- the stomach 1β in 
of a transgenic mouse model in response to infection resulted in inﬂammation, H. pylori 
dysplasia and enhanced gastric carcinogenesis. Whereas, IL-18 has been associated with   
increased metastasis and immune escape in gastric cancer cells (Huang et al., 2013 Kang et ; 
al., 2009). 
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Consequently, recognition of with NLRs, activation of inﬂammasome H. pylori 
complex and the downstream signaling pathways are essential for controlling H. pylori 
infection. Yet, these signaling pathways will limit the immunopathological tissue damages with 
eﬀector T cell responses. Therefore, these observations suggest a dual role for the 
inﬂammasome during infection (Mak'Anyengo et al., 2018). H. pylori 
4.2. Eﬀector T cell response to H. pylori 
 CD4+ T cells are the key eﬀector cells of adaptive immunity in the immune response to 
H. pylori compared to the relatively inactive role of CD8 T cells.The immune response was 
originally considered as a Th1 response but other CD4+ T cell subsets including Th17 and 
Tregs have been introduced in infection (Bagheri et al., 2018b). Generally, activation H. pylori 
of Th1 and Th17 cells follows with consequent production of IFN- γ,  IL α -17, and TNF-
(Bagheri et al., 2018a). Neutrophils and monocytes in response to the neutrophil activating 
protein of (HP-NAP) produce IL-12 that promote Th1 responses. Furthermore, Th1 H. pylori 
cells in response to HP-NAP producing IFN-γ  in  the  gastric  mucosa  cause  chronic  gastric 
inﬂammation (Amedei et al., 2006) . In addition, Th17 cells appear to be essential in the 
clearance of . IL-17 facilitates the release of IL-8 that promote gastric inﬂammation. H. pylori
On the other hand, IL-8 recruits neutrophils that are critical for the clearance of the bacteria 
(Luzza et al., 2000). Moreover, in the distal gastric adenocarcinoma, a part of Th cells show 
signiﬁcant  proliferation to the peptidyl-prolyl cis-trans isomerase of (HP0175)H. pylori . 
HP0175 induces high level of -17 and IL-21 production by lymphocytes, thus promoting IL
Th17 responses (Amedei et al., 2014). IL-21 is a complicated cytokine that modulates the 
diﬀerentiation of CD4+ and CD8+ T cells in context dependent manner. Although, IL-21 
promotes Th17 diﬀerentiation and IL-10 production, but inhibits the generation of potentially 
pathogenic Th1 and Th17 eﬀector cells (Tian and Zajac, 2016). These Th17 cells had reduced 
cytolytic activity, while helping to monocyte matrix metalloproteinase-2 (MMP-2), matrix 
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metalloproteinase-9 (MMP-9), and vascular endothelial growth factor (VEGF) production. 
Hence, HP0175 provides a link between relH. pylori ated inﬂammation and gastric cancer. Th1 
and Th17 cells are involved in enhancing the immunopathologic and histopathologic changes 
of the gastric mucosa that result in gastric inﬂammation, atrophic gastritis, epithelial 
hyperplasia, and intestinal metaplasia in chronic infections (Hitzler et al., 2012a Larussa et al., ; 
2015) In contrast, Tregs that produced during infection contribute to bacterial . H. pylori 
persistence. Tregs protect the host cells infected with against excessive gastric H. pylori 
inﬂammation and may also promote bacterial colonization which may lead gastric tumor to 
progression (Laur et al., 2016) . 
4.2.1. Evasion of Th1 and Th17 cells 
A prominent feature of infection is that eﬀector T cell responses are  H. pylori 
mostly impaired during infection leading to hyporesponsivity or anergy of T cells. H. pylori 
virulence factors contributing in -interfering  with  T  cell  responses  are  VacA,  γ
glutamyltranspeptidase (GGT), and arginase (Rimbara et al., 2013) VacA inhibits the     . 
proliferation of T cells. First, VacA binds to an unknown receptor on T cells which inhibits cell 
proliferation through actin rearrangement. Secondly, VacA binds to the mitochondria and 
leading to apoptosis. This mechanism is able to induce inhibition of T cell proliferation (Abadi, 
2017). Furthermore, VacA inhibits the proliferation of T cells via interfering with the signaling 
pathway of TCR- -2 and upstream molecules such as calcium/calmodulin-dependent IL
phosphatase calcineurin. VacA also prevents nuclear translocation of the nuclear factor of 
activated T cells (NFAT) transcription factor and consequent inhibits transcription of speciﬁc ly 
T cell genes (Gebert et al., 2003) Further studies identiﬁed integrin (CD18) on T cells act  . β2 
as VacA receptor. The integrin β2 along with CD11a creates lymphocyte function-associated 
antigen-1 (LFA-1) on the surface of the T cell (Sewald et al., 2008) . 
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In addition to Vac A, GGT is able to inhibit T cell proliferation. The GGT mediates 
the extracellular cleavage of glutathione and through ROS production leading cell cycle to 
arrest in lymphocytes. GGT disrupts Ras signaling pathway that result in G1 cell cycle arrest 
and then inhibits T cell proliferation (Lina et al., 2014). 
B7-H2 (ICOS-L) is a new member of the B7-family receptors that have the -stimulatory co
function on T cell activity upon binding to inducible costimulator ICOS). Recently, the B7-(
H2/ICOS interaction in Th17 cell development, maintenance and function has been 
identiﬁed. The virulence factor CagA also shows a key role in the dulation of Th17 cell mo
response indirectly through restricting expression of B7-H2 on gastric epithelial cells. Th17 
suppression leads to the persistence of infection in stomach (Lina et al., 2013)H. pylori  . 
4.2.2. Deviation in T cell response 
Unusual activation of Tregs by microbial antigens may provide a mechanism of H. 
pylori evasion from immune response. The gamma-glutamyl transpeptidase (GGT) and VacA 
from molecules indirectly aﬀect the activity of T lymphocytes and promote the H. pylori 
diﬀerentiation of eﬀector CD4+ T cells to Tregs (Oertli et al., 2013) The gastric mucosal   . 
inﬂammatory response to could be modulated by Tregs, which is characterized with H. pylori 
the expression of transcription factor FOXP3, CD25, and production of IL-10. Tregs can 
suppress cytokine proliferation and production of other T cells (Algood and Cover, 2006) The . 
interaction between the naïve CD4+ T cell and tolerogenic dendritic cells exposed to H. pylori 
is crucial for Tregs diﬀerentiation In addition, gastric epithelial cells exposed to . H. pylori 
induced Tregs. This interaction mostly happens in the gastric mucosa or the mesenteric lymph 
nodes (Lina et al., 2014 Salama et al., 2013) Dendritic cells that are exposed to  ; . H. pylori in 
vivo in vitro and cannot induce Th1 and Th17 responses, while they induce Tregs expression. 
It seems that the induction of Tregs is dependent on the age when the host gets the infection. 
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Hence, the level of Tregs in children with infection has increased, and gastric H. pylori 
pathology has reduced in comparison with adults (Oertli and Muller, 2012) 
 A study showed that outer inﬂammatory protein A (OipA) of is a DC H. pylori 
maturation suppression factor. In fact, OipA helps the establishment of chronic H. pylori 
infection through decreasing IL-10 levels and suppressing DC maturation. Hence, tolerogenic 
programming in DCs by H. pylori lead to persistent gastric colonizations  (Teymournejad et al., 
2014) Furthermore, -induced tolerogenic DCs are not able to induce eﬀector . H. pylori
functions in naive T cells, and these cells became very eﬃcient in inducing Tregs (Lina et al.,  
2014) Therefore in this context with dominant Treg-induced responses, there was a high . 
tendency for the control in chronic infection conditions (Bagheri et al., 2016) In H. pylori  . H. 
pylori infected human especially in children and asymptomatic carriers, Tregs are accumulated 
in the gastric mucosa and eﬀectively inhibits the response of speciﬁc T cell memory against 
H. pylori (Lundgren et al., 2003) On the other hand, the experiments on vaccinated mice . 
showed that the depletion of Tregs can facilitate the removal of in infected animals H. pylori 
and increases vaccine protection (Anderl and Gerhard, 2014) Tregs facilitating   . H. pylori 
persistence required T-cell expressing IL-10. In fact, deﬁcient -10 animals are capable IL
controlling experimental infections spontaneously, while control or even clearance of H. pylori 
in various animals has led to signiﬁcant changes in stomach immunopathology such as atrophy 
and metaplasia.(Liu et al., 2016) In addition to the presence of Tregs, their potential for 
inducing the tolerance of -speciﬁc dendritic cells is critical. In a study, it was shown H. pylori
that in spite of the abundant presence of Tregs, the high colonization of occurred in  H. pylori 
carriers and developed gastri (Raghavan and Quiding-Jarbrink, 2012) It seems that the tis  . 
activity of both VacA and GGT is required for T cell immune response deviation, but their 
exact mechanisms for inducing the tolerance of -speciﬁc dendritic cells is unclear. It H. pylori
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has recently been noted that the function of both factors is critical for Tregs induction (Oertli  
et al., 2013). 
5. Development of vaccine; hopes and failures H. pylori 
In early 1990, infection with was introduced as the main cause of peptic H. pylori 
ulcer and a serious risk factor for gastric cancer development. Gastric carcinoma is now the 
third leading cause of the death due to malignancy and the majority of these cancers develop 
due to infection (Sutton and Boag, 2018). Hence, a vaccine against the H. pylori H. pylori 
would be a powerful tool to prevent gastric carcinoma. Eﬀorts for vaccine H. pylori 
development has begun for a quarter of century now, and countless eﬀorts were made to 
produce an eﬀective vaccine. (Talebi Bezmin Abadi, 2016) However, the development of . 
vaccine against was found to be extremely challenging as vaccines in clinical trials H. pylori 
were found to be less eﬀective. 
 In this context, the best preclinical result was obtained from vaccines that often 
induced T cell-mediated immune response rather than humoral immunity. Th1 and Th17 
responses in the stomach are more protective (Sun et al., 2018) The common immunogenic  . 
antigens of that were able to produce immunity in mice models are urease enzymes, H. pylori 
CagA, VacA, neutrophil activating proteins (NAPs), and heat shock proteins (HSP). These 
antigens can enter the stomach via various mucosal routes such as intranasal, sublingual and 
rectal. Additionally, systemic immunization through intraperitoneal and subcutaneous routes 
can be more eﬀective for vaccination Vaccination involving these wide range of H. pylori . 
antigens, adjuvants, and delivery systems yielded only a partial reduction of bacterial 
colonization in mice, and thus are less eﬀective. persistence mechanisms and H. pylori 
utilization of a wide range of mechanisms to overcome adaptive immunity are recognized as 
important barriers to vaccination (Robinson et al., 2017) . 
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The partial success achieved in animal models has not translated protection in to 
clinical trials, although with few exceptions. A clinical phase III trial conducted in China with 
a prophylactic vaccine containing a fusion protein of urease with heat-labile toxin B E. coli 
subunit has shown promising reduction in H. pylori natural infections in children. The vaccine 
given to children aged 6-15 is found to be eﬀective in prevention of natural acquisition of H. 
pylori infections in 71.8% participants after one year and 55% participants after two years. 
However, the vaccine may unlikely be feasible for the global distribution in the current 
formulation since vaccine recipients need to be given bicarbonate solution 2h prior to oral 
vaccination to reduce stomach acids which can degrade the vaccine. Also, the vaccine eﬃcacy 
can wane after one year needing frequent vaccinations. Nonetheless, this study might be the 
ﬁrst demonstration that an eﬀective vaccine can be developed against infection (Zeng H. pylori 
et al., 2015). A phase I clinical trial showed that intramuscular immunization with the three 
CagA, VacA, and NAPs recombinant antigens combined with alum adjuvant is found to be 
immunogenic to some or all of the antigens. The T cell response to CagA and VacA antigens 
was detectable up to 24 months after the ﬁrst vaccination and provided a protective response 
(Malfertheiner et al., 2008) However, this vaccine developed by Novartis has not been pursued . 
for further trials. Another phase I clinical trial involving oral therapeutic vaccination of H. 
pylori E. coli urease with heat-labile enterotoxin has shown potential eﬃcacy, with small 
reductions in colonization of (Michetti et al., 1999). Evidence also suggests that oral H. pylori 
vaccination with serovar TY21a expressing urease can Salmonella enterica typhi H. pylori 
stimulate cell mediated immune response and reduces infection (Londono-Arcila et al., 2002). 
The most important eﬀorts that have been made in the past for the vaccine as well as H. pylori 
the prospects for the future are summarized in table 1. Therefore, it seems that the eﬀorts for 
H. pylori vaccine development are in primary steps of a long road and will require more   
diligence and attention in the future. 
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6. Conclusion 
 Eﬀorts to develop speciﬁc treatments of were initiated concurrent with the H. pylori ly 
identiﬁcation of bacter as the main cause of gastric ulcer and a risk factor for gastric cancer ia 
(Lina et al., 2014). virulence factors such as CagA, VacA, and HP-NAP cause major H. pylori 
damages in the gastric epithelium which results in gastrointestinal disorders including peptic 
ulcer or gastric cancer. Beside these, deviation in host immune responses determines the 
severity of gastrointestinal disorders. Immune evasion mechanisms are recognized as a 
remarkable challenge for development of speciﬁc therapies to overcome gastrointestinal 
disorders that are associated with infection. Although the host immune responses H. Pylori 
clears most pathogens, but evolved a set of mechanisms to evade both innate and H. pylori 
adaptive immune responses that guarantees bacterial persistence. In fact, immune response     
can’t clear the bacterium but facilitates the bacterial colonization and survival in stomach. 
(Abadi, 2017 Lina et al., 2014 Mejias-Luque and Gerhard, 2017) . On the other hand, ; ; 
vaccination against infection as promising strateg is facing with drastic challenges. H. pylori y 
Therefore, vaccination strategies that lead to protective immune response by generating Th1 
and Th17 responses in the stomach was more reliable than Tregs dependent responses in 
preclinical animal models. Taken together, a better understanding of and host cells  H. pylori 
interaction is critical for the development of speciﬁc protection and treatment in the future. 
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Table 1. Approaches was applied in H. pylori vaccine in past and may be examined in future 
 
Past experimental approaches to H. pylori vaccine 
 
Vaccine 
(Antigen + Adjuvant) 
 Route Result  Ref 
Urease + LT Oral Decrease of bacterial load in 
vaccinated groups 
(Michetti et 
al., 1999) 
Whole cell + dmLT Oral No bacterial clearance (Kotloﬀ et al., 
2001) 
Urease or HP0231 
 + Salmonella Ty21a 
Oral Bacterial clearance in both 
vaccinated and control 
(Aebischer et 
al., 2008) 
Urease + LT Oral Eﬃcacy 72% (Zeng et al., 
2015) 
CagA, VacA, NAP 
+ Alum 
IM Clearance equivalent between 
vaccinated and 
(Malfertheiner 
et al., 2018) 
 
Newer experimental approaches to H. pylori vaccine 
 
Multi-epitope DNA-prime/peptide 
(EpiVax) 
IN Some therapeutic 
protection in mice 
(Moss et al., 
2011) 
GGT (Imevax/IMX101 X) IP Protection against allergic 
asthma 
(Oertli et al., 
2013) 
Lactococcus lactis expressing CTB 
and urease (Probiotic vaccine) 
Oral  (Li et al., 
2014) 
UreI-UreB + CTB 
(Urease epitope vaccine) 
Oral Limited protection in BALB/c 
mice 
(Yang et al., 
2015) 
Lp220 + CTB IP Limited protection in BALB/c 
mice 
(Li et al., 
2016) 
A non-pathogenic Vibrio cholerae 
strain engineered to express HpaA, 
UreB and FlaA (Helicovaxor® ) 
Oral Introduced as oral inactivated 
vaccine 
(Tobias et al., 
2017) 
 
CTB, cholera toxin subunit B; dmLT, double mutant LT; , gamma-glutamyl-transpeptidase; IM, GGT
intramuscular; IN, intranasal; IP, intraperitoneal; LT, heat-labile enterotoxin; UreI-UreB, Escherichia coli H. 
pylori urease I and urease B 
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 Figure legend 
 
Fig.1 evasion mechanisms from immune responses. After enters to the H. pylori H. pylori in
lumen of stomach, urease locally raises the pH, and promotes bacterial persistence and activity 
motility. After bacterial attachment the epithelial cells, VacA and CagA virulence proteins  to 
are injected to the host cells causing a number of changes including disruption of cell polarity 
and apoptosis. When the bacterium arrives to submucosa, DC act as the main antigen presenting 
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cells and determine the fate of immune responses. The peptidoglycan of is delivered H. pylori 
to the NOD1 through T4SS. Activated NOD1 induces expression of pro-inﬂammatory 
cytokines through AP-1 and NF B. In addition, NOD1 signaling results in type I IFNs ‑ κ
expression via IRF3 and IRF7. Furthermore, NLR ligands in endosomes activate the H. pylori 
inﬂammasome that conduct the 1 and ILIL‑ β ‑ 18 processing. so, exposed DCs Al GGT 
produce IL‑ ‑ 10. IL 18 and Il-10 binds to its receptor on naive T cells and induce FOXP3 
dependent CD4+CD25+ Treg cell that followed by persistent colonization of . On the H. pylori
other hand, IL‑ 1 binding to its receptor induces Th1 and Th17 diﬀerentiation via Tbet and β 
ROR t transcription factors, respectively. Bacterial clearance increases in the presence of Th1 γ
and Th17 dependent immune responses. In contrast, secreted 10 from DCs or Tregs further IL‑ 
suppresses Th1 and Th17 eﬀector functions. ASC, apoptosis associated speck like protein ‑ ‑ 
containing a CARD; CARD, caspase activation and recruitment domain; GGT, 
γ‑ glutamyl transpeptidase; LRR, leucine rich repeat domain; 1 , interleukin 1‑ ‑ IL‑ β ‑ β; 
IL‑ ‑ ‑ 18, interleukin 18; MAPK, mitogen activated protein kinase; NF B, nuclear ‑ κ
factor B; NOD1, nucleotide binding oligomerization domain containing 1 ROR t, ‑ κ ‑ ‑ ; γ
retinoid related orphan receptor PAI, pathogenicity island; Tbet, T box transcription ‑ γt; ‑ 
factor; Th1, T helper 1; Th17, T helper 17; Treg, regulatory T cells; T4SS, type IV secretion 
system. 
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